Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
about
Validity and reliability of the Dutch adaptation of the Psoriatic Arthritis Quality of Life (PsAQoL) QuestionnaireTNF-alpha inhibitors for psoriatic arthritisPsoriasis: epidemiology, clinical features, and quality of lifeMaking the next steps in psoriatic arthritis management: current status and future directionsMeasures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds EnClinical outcomes in psoriatic arthritis: A systematic literature reviewPsychometric properties of a new treatment expectation scale in rheumatoid arthritis: an application of item response theoryImprovements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies.Adaptation of the Psoriatic Arthritis Quality of Life (PsAQoL) instrument for Sweden.Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey.Phenotypic and clinical differences between Caucasian and South Asian patients with psoriatic arthritis living in North East London.Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity in patients with psoriatic arthritisImprovements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised plaPsoriatic arthritis: epidemiology, clinical features, course, and outcome.Psoriatic arthritis assessment tools in clinical trials.Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint diseases?A case-study in the clinical epidemiology of psoriatic arthritis: multistate models and causal arguments.Seronegative spondyloarthropathies: to lump or split?Adaptation of Chinese and English versions of the Psoriatic Arthritis Quality of Life (PsAQoL) scale for use in SingaporeMeasuring disease activity in psoriatic arthritis.Assessing quality of life in older adult patients with skin disorders.Treatment goals in psoriasis.Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-CanadianAssessment of health-related quality of life in menopause and aging.An educational leaflet improves response to invitation for screening for arthritis in patients with psoriasis in primary care, but only in practices in the most deprived areas.Real-life experience of using conventional disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA). Retrospective analysis of the efficacy of methotrexate, sulfasalazine, and leflunomide in PsA in comparison to spondyloarthritidDrug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritis.Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting.The perspective on psoriatic arthritis in Asia.Management of psoriatic arthritis from the view of the dermatologist.Burden of disease: psoriasis and psoriatic arthritis.Diagnosing and treating psoriatic arthritis: an update.Patient involvement in outcome measures for psoriatic arthritis.A review of disease activity measures for psoriatic arthritis: what is the best approach?Patient-reported outcome measures in psoriasis: the good, the bad and the missing!The impact of disease severity, illness beliefs and coping strategies on outcomes in psoriatic arthritis.Assessing disease activity in psoriasis and psoriatic arthritis: impact on management and therapy.Patient-Reported Outcomes in Psoriatic Arthritis.A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis.
P2860
Q21133692-7BA61E36-BF1C-4E05-AC33-1728A1792A1BQ24240905-34BFBA16-4831-453A-9D10-161EB3C13814Q24675003-9B6EEE55-3F5B-4169-9992-E3BA18E71A2EQ26783506-3A18EE06-0370-41BE-B005-5CB8916B445DQ26862017-33FD1A10-5BF3-4639-A29B-7E3C678A4E92Q26995307-4B9DA5C8-75FF-445F-9D34-D4E967482351Q30663698-D22019DA-BF03-408E-80F4-B6A1D0B489FBQ34017619-CC1C050C-76D8-4FFB-9198-3E41F6162797Q34092035-1B1A71A4-C480-4BB9-8D97-26C528DCC8E0Q34099501-01E09945-B627-42EC-A725-30C948FD26E6Q34318229-C2198FB4-00E9-4391-8183-18895EF0C441Q34485175-BF0D92AF-FBDB-4BD0-933E-7083F0AEBB46Q34818891-6AADF0C4-90F4-4B6B-8C8C-26159B900309Q35579437-68FD6738-536A-48A4-A852-058B402FF490Q35579462-6DBC95D0-B128-4A2E-B30B-CD85D97A746BQ35638265-DE41A0B1-B67B-4B4A-BF0D-0AD7D6B95FECQ35673043-8C7BB333-A207-452C-AEEC-754AC1C141A8Q36040093-67CA808E-0DF9-49BA-98F0-3C83F931BCD1Q36166729-D72CFB3B-D185-4DB0-80AF-BEEBC9BD39ACQ36520126-67197B9B-6F4F-416F-828F-3416567BB44CQ36648569-5C1C7D61-3C08-4217-8BC2-C6F498DB1163Q36870158-2F888B91-45BD-4794-8AEB-2575AE0F108CQ37036355-13732526-9B58-4DB5-A98F-0B1123020AFCQ37114630-DC209F40-E91B-48E8-9AD0-A38B4F1B9566Q37118799-73E5BBB8-57B4-4AE8-A654-4EE0E71EF0F7Q37662772-42DFC51D-1C18-4437-BC49-8BDB2FE096E8Q37679286-ABA30407-324E-4D71-865E-C7DAD781F49CQ37826195-9533ADA2-52C2-429B-9D70-736633486D1AQ37862369-9ABBBDD2-F808-4224-9A2F-7AD3B01432C7Q37873357-9ACC61D5-84E4-4434-A874-482687AF977DQ37930978-20891A22-5BE8-4871-8E08-05764B5C41E8Q38114850-E23C9A72-570A-4689-B4EC-41C4C98CBEE9Q38165235-53199A70-40A5-45D3-87B0-ADE060CB8D13Q38195568-130C7D3F-0AE1-486D-B43A-E6CC8DA904CAQ38236514-AD6698F7-A6A6-4179-B48D-0FC6E55D7104Q38354062-292B70CE-8E01-4867-A34B-84FE05BA6F49Q38644022-49C827C7-7D22-4C2C-ABF8-7B11869C4E2AQ38710469-17E957DD-FE13-4F44-87EC-D4796992CCB5Q38822369-89B6E08E-A901-4CC4-A4B7-5AB2E252A1A2Q38858335-E5FF9F69-D5FA-4B76-A83B-A60FDB9AD6BD
P2860
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
@ast
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
@en
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
@en-gb
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
@nl
type
label
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
@ast
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
@en
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
@en-gb
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
@nl
prefLabel
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
@ast
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
@en
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
@en-gb
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
@nl
P2093
P2860
P3181
P356
P1476
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
@en
P2093
P2860
P3181
P356
10.1136/ARD.2003.006296
P407
P50
P5530
P577
2004-02-01T00:00:00Z
P5875
P6179
1044845286